抗血栓药物在不同年龄段上消化道出血患者中的应用

IF 2 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Gastroenterology Research and Practice Pub Date : 2024-04-04 DOI:10.1155/2024/1710708

Ding Peng, Huihong Zhai

{"title":"抗血栓药物在不同年龄段上消化道出血患者中的应用","authors":"Ding Peng, Huihong Zhai","doi":"10.1155/2024/1710708","DOIUrl":null,"url":null,"abstract":"<i>Objective</i>. This study aimed at exploring the safety and timing of antithrombotic drugs in different age-group patients with UGIB. <i>Methods</i>. An observational study retrospectively based on the single-center database with 713 patients with UGIB. <i>Result</i>. Among the 713 patients, 62.13% were elderly patients (<span><svg height=\"12.7112pt\" style=\"vertical-align:-3.403299pt\" version=\"1.1\" viewbox=\"-0.0498162 -9.3079 35.429 12.7112\" width=\"35.429pt\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><g transform=\"matrix(.013,0,0,-0.013,0,0)\"></path></g><g transform=\"matrix(.013,0,0,-0.013,5.642,0)\"></path></g><g transform=\"matrix(.013,0,0,-0.013,11.621,0)\"></path></g><g transform=\"matrix(.013,0,0,-0.013,17.212,0)\"></path></g><g transform=\"matrix(.013,0,0,-0.013,27.798,0)\"></path></g></svg><span></span><svg height=\"12.7112pt\" style=\"vertical-align:-3.403299pt\" version=\"1.1\" viewbox=\"39.0111838 -9.3079 12.655 12.7112\" width=\"12.655pt\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><g transform=\"matrix(.013,0,0,-0.013,39.061,0)\"></path></g><g transform=\"matrix(.013,0,0,-0.013,45.301,0)\"></path></g></svg></span> years) and the mortality was 2.9%. In elderly patients with UGIB, we found that previous medication history, resumption of medication, and time of resumption did not affect the in-hospital mortality. The resumption of anticoagulants increased the risk of rebleeding. The independent risk factors of mortality were CHF, cirrhosis, creatine kinase, and albumin. The independent risk factors of rebleeding were the application of anticoagulants during hospitalization, variceal bleeding, black stool, red blood cells (lab), platelets (lab), and heart rate. <i>Conclusions</i>. In UGIB patients, a history of antiplatelet or antithrombotic drugs and the use of antiplatelet drugs after UGIB did not affect the patient’s prognosis. In elderly UGIB patients, although antithrombotic drugs did not increase the risk of death, the increased risk of rebleeding after resumption of use deserved careful treatment. It was safe to recover anticoagulant drugs as soon as possible in young UGIB patients.","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"49 1","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Application of Antithrombotic Drugs in Different Age-Group Patients with Upper Gastrointestinal Bleeding\",\"authors\":\"Ding Peng, Huihong Zhai\",\"doi\":\"10.1155/2024/1710708\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<i>Objective</i>. This study aimed at exploring the safety and timing of antithrombotic drugs in different age-group patients with UGIB. <i>Methods</i>. An observational study retrospectively based on the single-center database with 713 patients with UGIB. <i>Result</i>. Among the 713 patients, 62.13% were elderly patients (<span><svg height=\\\"12.7112pt\\\" style=\\\"vertical-align:-3.403299pt\\\" version=\\\"1.1\\\" viewbox=\\\"-0.0498162 -9.3079 35.429 12.7112\\\" width=\\\"35.429pt\\\" xmlns=\\\"http://www.w3.org/2000/svg\\\" xmlns:xlink=\\\"http://www.w3.org/1999/xlink\\\"><g transform=\\\"matrix(.013,0,0,-0.013,0,0)\\\"></path></g><g transform=\\\"matrix(.013,0,0,-0.013,5.642,0)\\\"></path></g><g transform=\\\"matrix(.013,0,0,-0.013,11.621,0)\\\"></path></g><g transform=\\\"matrix(.013,0,0,-0.013,17.212,0)\\\"></path></g><g transform=\\\"matrix(.013,0,0,-0.013,27.798,0)\\\"></path></g></svg><span></span><svg height=\\\"12.7112pt\\\" style=\\\"vertical-align:-3.403299pt\\\" version=\\\"1.1\\\" viewbox=\\\"39.0111838 -9.3079 12.655 12.7112\\\" width=\\\"12.655pt\\\" xmlns=\\\"http://www.w3.org/2000/svg\\\" xmlns:xlink=\\\"http://www.w3.org/1999/xlink\\\"><g transform=\\\"matrix(.013,0,0,-0.013,39.061,0)\\\"></path></g><g transform=\\\"matrix(.013,0,0,-0.013,45.301,0)\\\"></path></g></svg></span> years) and the mortality was 2.9%. In elderly patients with UGIB, we found that previous medication history, resumption of medication, and time of resumption did not affect the in-hospital mortality. The resumption of anticoagulants increased the risk of rebleeding. The independent risk factors of mortality were CHF, cirrhosis, creatine kinase, and albumin. The independent risk factors of rebleeding were the application of anticoagulants during hospitalization, variceal bleeding, black stool, red blood cells (lab), platelets (lab), and heart rate. <i>Conclusions</i>. In UGIB patients, a history of antiplatelet or antithrombotic drugs and the use of antiplatelet drugs after UGIB did not affect the patient’s prognosis. In elderly UGIB patients, although antithrombotic drugs did not increase the risk of death, the increased risk of rebleeding after resumption of use deserved careful treatment. It was safe to recover anticoagulant drugs as soon as possible in young UGIB patients.\",\"PeriodicalId\":12597,\"journal\":{\"name\":\"Gastroenterology Research and Practice\",\"volume\":\"49 1\",\"pages\":\"\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gastroenterology Research and Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/2024/1710708\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterology Research and Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2024/1710708","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

研究目的本研究旨在探讨不同年龄组 UGIB 患者使用抗血栓药物的安全性和时机。方法基于单中心数据库对 713 例 UGIB 患者进行回顾性观察研究。结果在 713 例患者中，62.13% 为老年患者（岁），死亡率为 2.9%。在老年 UGIB 患者中，我们发现既往用药史、恢复用药和恢复用药的时间并不影响院内死亡率。抗凝药物的恢复会增加再出血的风险。死亡率的独立风险因素是心房颤动、肝硬化、肌酸激酶和白蛋白。再出血的独立危险因素是住院期间应用抗凝剂、静脉曲张出血、黑便、红细胞（实验室）、血小板（实验室）和心率。结论在 UGIB 患者中，抗血小板或抗血栓药物史以及 UGIB 后使用抗血小板药物不会影响患者的预后。在老年 UGIB 患者中，虽然抗血栓药物不会增加死亡风险，但恢复使用后再出血的风险增加，值得谨慎治疗。对于年轻的 UGIB 患者，尽快恢复使用抗凝药物是安全的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Application of Antithrombotic Drugs in Different Age-Group Patients with Upper Gastrointestinal Bleeding

Objective. This study aimed at exploring the safety and timing of antithrombotic drugs in different age-group patients with UGIB. Methods. An observational study retrospectively based on the single-center database with 713 patients with UGIB. Result. Among the 713 patients, 62.13% were elderly patients ( years) and the mortality was 2.9%. In elderly patients with UGIB, we found that previous medication history, resumption of medication, and time of resumption did not affect the in-hospital mortality. The resumption of anticoagulants increased the risk of rebleeding. The independent risk factors of mortality were CHF, cirrhosis, creatine kinase, and albumin. The independent risk factors of rebleeding were the application of anticoagulants during hospitalization, variceal bleeding, black stool, red blood cells (lab), platelets (lab), and heart rate. Conclusions. In UGIB patients, a history of antiplatelet or antithrombotic drugs and the use of antiplatelet drugs after UGIB did not affect the patient’s prognosis. In elderly UGIB patients, although antithrombotic drugs did not increase the risk of death, the increased risk of rebleeding after resumption of use deserved careful treatment. It was safe to recover anticoagulant drugs as soon as possible in young UGIB patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Gastroenterology Research and Practice GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Gastroenterology Research and Practice is a peer-reviewed, Open Access journal which publishes original research articles, review articles and clinical studies based on all areas of gastroenterology, hepatology, pancreas and biliary, and related cancers. The journal welcomes submissions on the physiology, pathophysiology, etiology, diagnosis and therapy of gastrointestinal diseases. The aim of the journal is to provide cutting edge research related to the field of gastroenterology, as well as digestive diseases and disorders. Topics of interest include: Management of pancreatic diseases Third space endoscopy Endoscopic resection Therapeutic endoscopy Therapeutic endosonography.